VacZine Analytics  
MarketVIEW: Rhinovirus vaccines

Now part of MasterVIEW 2020
Click here>>

Human rhinovirus (HRV) is the major causes of the common cold. It can cause of morbidity in patients with chronic respiratory diseases, as well as infants and the elderly. In individuals with asthma, COPD and cystic fibrosis, HRV is associated with acute exacerbations that generate high healthcare costs largely due to hospitalizations. HRV also causes bronchiolitis in infants and respiratory illness in older adults. The treatment of HRV infection is primarily supportive, including over-the-counter products aimed at symptom relief.

A broadly-protective HRV vaccine may have a significant public health impact if it could reduce or prevention of exacerbations in COPD and asthma patients. This should result in significant healthcare cost savings as hospitalization is a key direct cost during an episode. There are currently no HRV vaccines in active clinical development. Preclinical activity is ongoing.

This MarketVIEW is a comprehensive MS Excel-based model + summary presentation that forecasts the potential commercial value of Rhinovirus vaccines across Western markets to 2030. Each model contains value ($ m) and volume (mio doses) predictions along with launch timeframe, TPP, pricing and penetration estimates. LO/BASE/HI forecast scenarios are included based upon a differing pricing justifications. An up to date review is also given for latest disease background and epidemiology, along with current R&D status.


To order please contact your region account manager, buy "on-line" or order direct at:

VAMV066 Click here>>
Choose option:
*Prices quotes are for 1 region license only. Regions are North America, or EU or ROW. For UK orders VAT will be added at 20%. Please review the TERMS and CONDITIONS of purchase.

Return to main list>> Questions about this report?

© 2016 VacZine Analytics. All rights reserved. Disclaimer | Privacy | Terms and conditions. hosted by chillydomains